Research programme: anti-transglutaminase 2 monoclonal antibodies - Quark Pharmaceuticals

Drug Profile

Research programme: anti-transglutaminase 2 monoclonal antibodies - Quark Pharmaceuticals

Alternative Names: anti-TGase II monoclonal antibodies - Quark Pharmaceuticals

Latest Information Update: 07 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Quark Biotech
  • Developer Quark Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Immunostimulants; Transglutaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic nephropathies; Fibrosis; Renal failure

Most Recent Events

  • 19 Dec 2006 Preclinical trials in Diabetic nephropathies in USA (Parenteral)
  • 19 Dec 2006 Preclinical trials in Fibrosis in USA (Parenteral)
  • 19 Dec 2006 Preclinical trials in Renal failure in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top